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Background: Dementia prevalence is increasing as populations live longer, with no cure and the costs of caring
exceeding many other conditions. There is increasing evidence for modifiable risk factors which, if addressed in
mid-life, can reduce the risk of developing dementia in later life. These include physical inactivity, low cognitive
activity, mid-life obesity, high blood pressure, and high cholesterol. This study aims to assess the acceptability and
feasibility and impact of giving those in mid-life, aged between 40 and 60 years, an individualised dementia risk
modification score and profile and access to personalised on-line health information and goal setting in order to
support the behaviour change required to reduce such dementia risk. A secondary aim is to understand participants’
and practitioners’ views of dementia prevention and explore the acceptability and integration of the Innovative Midlife
Intervention for Dementia Deterrence (In-MINDD) intervention into daily life and routine practice.
Methods/design: In-MINDD is a multi-centre, primary care-based, single-blinded randomised controlled feasibility trial
currently being conducted in four European countries (France, Ireland, the Netherlands and the UK). Participants are
being recruited from participating general practices. Inclusion criteria will include age between 40 and 60 years; at least
one modifiable risk factor for dementia risk (including diabetes, hypertension, obesity, renal dysfunction, current
smoker, raised cholesterol, coronary heart disease, current or previous history of depression, self-reported sedentary
lifestyle, and self-reported low cognitive activity) access to the Internet. Primary outcome measure will be a change in
dementia risk modification score over the timescale of the trial (6 months). A qualitative process evaluation will interview
a sample of participants and practitioners about their views on the acceptability and feasibility of the trial and the links
between modifiable risk factors and dementia prevention. This work will be underpinned by Normalisation Process
Theory.
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Discussion: This study will explore the feasibility and acceptability of a risk profiler and on-line support environment to
help individuals in mid-life assess their risk of developing dementia in later life and to take steps to alleviate that risk by
tackling health-related behaviour change. Testing the intervention in a robust and theoretically informed manner will
inform the development of a future, full-scale randomised controlled trial.
Trial registration: ISRCTN Registry: ISRCTN 98553005 (DOI: 10.1186/ISRCTN98553005).
Keywords: Dementia, Primary prevention, Modifiable risk factors, Internet, Primary careBackground
Dementia is a serious loss of cognitive ability beyond
what might be expected from normal ageing, with Alzhei-
mer’s disease and vascular dementia, the commonest types
[1]. Current estimates suggest a worldwide prevalence of
dementia in those aged 60 and over at 5 to 7 %, with num-
bers increasing from 35.6 million in 2010 to an estimated
115.4 million in 2050 [2, 3]. In 2010, the global cost of
dementia and the associated needs for care were put at
£391 billion (€533 billion, US $604 billion) [1]. In the
UK, for example, dementia costs the economy £17 billion
(€23 billion, $26 billion) per annum—more than cancer
and heart disease combined [4]. In addition to the eco-
nomic and caring burdens, dementia is a condition that
arouses fear and uncertainty. Currently incurable, the onset
and development of dementia can create an enormous
sense of insecurity for individuals and their families. Re-
search has demonstrated high levels of anxiety amongst
middle-aged and young-old individuals about their mem-
ory. This is compounded by the debilitation that can be as-
sociated with late-stage dementia, making it one of the
most feared conditions in relation to ageing [5, 6]. Taken
together, there is a clear need to not only develop treat-
ments for those with dementia, but to develop our under-
standing of the ways in which dementia risk might
addressed and reduced in those still in mid-life, well before
the onset of dementia. This is the aim of Innovative Midlife
Intervention for Dementia Deterrence (In-MINDD).
Risk factors associated with dementia
Several risk factors have been identified which can either
augment or reduce one’s risk of developing dementia [6, 7].
Some are non-modifiable, in particular age and genetic
factors such as apolipoprotein Ɛ4 [8]. An increasing body
of evidence is, however, highlighting a role for modifiable
risk factors which exacerbate, or reduce, one’s risk of
developing dementia in later life. Systematic reviews of
observational studies and randomised controlled trials
have examined the evidence for the influence of a range
of modifiable factors in later cognitive decline and de-
mentia [9–11]. Kloppenborg et al. found that diabetes,
hypertension, high cholesterol and obesity were each asso-
ciated with an increased risk of dementia, although the
evidence was most consistent for diabetes and obesity [9].Plassman and colleagues identified a range of potential
risk factors: depression, type 2 diabetes and smoking in-
creasing the risk; vegetable intake, Mediterranean diet,
increased physical and cognitive activity ameliorating it
[10]. However in general, the evidence identified was of
low quality and derived mainly from observational studies.
A later review calculated the population attributable risk
associated with seven modifiable risk factors (diabetes,
midlife hypertension, midlife obesity, smoking, depression,
physical inactivity, and low educational attainment) [11].
As well as finding that each risk factor alone increased
the relative risk of developing dementia in later life, the
authors also calculated that these seven risk factors to-
gether accounted for approximately 50 % of all cases of
Alzheimer’s dementia.
Two more recent papers have developed this evidence
base. Deckers et al. combined a systematic review of ob-
servational studies with a Delphi study which asked inter-
national experts in the field of dementia prevention and
epidemiology to rank and weight the identified risk factors
[12]. This study identified depression, midlife obesity,
high cholesterol, midlife hypertension, diabetes, physical
inactivity, and smoking as associated with an increased
risk of developing dementia in later life. Evidence relating
to diet, cognitive activity, coronary heart disease and renal
dysfunction was, however, inconclusive.
One criticism of some of this work has been the failure
to account for the interdependence of many of these risk
factors [13]. Thus, one recent paper has calculated the
population attributable risk for the seven risk factors
previously identified by Barnes and Yaffe [11]: the authors
calculated the individual risk, the combined risk and, ele-
gantly, the combined risk accounting for the interdepend-
ence of many of the risk factors (e.g. midlife obesity,
physical inactivity and low educational attainment) [14].
Even accounting for the inter-relationship of risk factors,
approximately 30 % of Alzheimer’s cases worldwide can
be attributed to the aforementioned risk factors of dia-
betes, midlife hypertension, midlife obesity, smoking,
depression, physical inactivity, and low educational
attainment.
This suggests that interventions targeting those in mid-
life to address health-related behaviour change around
modifiable risk factors might reduce both individuals’ risk
Table 1 Modifiable risk factors and conditions identified by In-
MINDD as potentially increasing or reducing dementia risk
(adapted from [12])
Risk/protective factor Relative risk from
published literature
Weight applied to factor
for LIBRA global score
Low/moderate alcohol
consumption
0.74 −1.0
Coronary heart disease 1.36 +1.0
Physical inactivity 1.39 +1.1
Renal dysfunction 1.39 +1.1
Diabetes 1.47 +1.3
Raised cholesterol level 1.54 +1.4
Smoking 1.59 +1.5
(Midlife) obesity 1.60 +1.6
(Midlife) hypertension 1.61 +1.6
Mediterranean diet 0.60 −1.7
Depression 1.85 +2.1
Cognitive activity 0.38 −3.2
O’Donnell et al. Pilot and Feasibility Studies  (2015) 1:40 Page 3 of 12of developing dementia in later life and, as a consequence,
the prevalence of dementia [11, 14, 15]. There is, how-
ever, a lack of public awareness about the link between
such modifiable risk factors and dementia risk [16, 17].
In addition, even if such links are made, such behaviour
change is not always easy.
Making and sustaining health behaviour change
Making and sustaining health behaviour changes, such
as stopping smoking or increasing physical activity, is
not easy [18, 19]. Interventions that utilise the Internet
and social media are increasingly seen as one potential
approach to empowering and sustaining individuals trying
to make and maintain such changes to their daily routine
[20–23]. Systematic reviews indicate that web-based
and eHealth interventions can be effective in supporting
behaviour change [24]. For example, web-based interven-
tions targeting smoking cessation [25] or increasing phys-
ical activity [26, 27] are effective in promoting, at least in
the short-term, the desired change in behaviour. In other
areas, however, the evidence is more equivocal, e.g. in
reducing alcohol consumption [28] or changing dietary
patterns [29]. There are similarly positive and negative
findings where multiple behaviours are targeted [30–32].
This variability in the findings may be due, in part, to the
quality of the underlying evidence base [31] or to a lack of
consideration of what components of the intervention are
the “active ingredients” [24]. Nevertheless, the potential to
scale up even moderately effective interventions to reach
large populations suggest that web-based interventions
are worth developing and testing.
There are, however, well-recognised problems associated
with scaling up the implementation of such approaches,
particularly in relation to sustainability and the embedding
of such approaches in both the daily lives of patients and
in the clinical routine of practitioners [33–36]. To address
these issues, Murray suggests that more attention to be
paid to early intervention development and testing and to
more explicit use of theory to inform the development of
and understand how interventions are embedded and
routinized by users [24]. This use of theory is supported
by Webb et al., who found that theoretically developed
web-based interventions were more effective at supporting
behaviour change [27]. It is these considerations which
have underpinned the methodological design of the
In-MINDD randomised controlled feasibility trial.
The Innovative Midlife Intervention for Dementia
Deterrence study
Funded by the EU Framework 7 programme, In-MINDD
brings together these two important concepts: first, that
there is a group of potentially modifiable and inter-linked
risk factors which, if addressed in mid-life, may reduce the
risk of developing dementia in later life, or at least delayits onset. Second, that on-line interactive tools may
help individuals make and—importantly—sustain health-
related behavioural change. Earlier work in In-MINDD
identified a group of modifiable risk factors and conditions
associated with dementia risk (Table 1) [12]. Using the
relative risks from the identified literature, the In-MINDD
team developed a risk score algorithm in which the rela-
tive risk of each factor was standardised and weighted to a
reference value, in this case, the relative risk for low/
moderate alcohol consumption. The final model, based
on the 12 risk factors shown in Table 1, is then used to
produce a personalised lifestyle for brain health (LIBRA)
global score and profile for individuals participating in
the feasibility trial (manuscript in preparation, Schiepers
et al.).
From this, we have developed an on-line profiler and
support environment which, based on individualised demo-
graphic, clinical and self-reported information on health-
related behaviours, can calculate an individual’s dementia
risk modification score. This information is given to indi-
viduals as a personalised LIBRA global score and profile,
highlighting areas of health-related behaviour in which they
are doing well (e.g. if they are a non-smoker); areas which
they cannot change but need to manage (e.g. if they have
diabetes) and areas where they could make improve-
ments (e.g. by increasing physical activity). This is illus-
trated in Fig. 1.
In addition to the LIBRA score and profile, there is a
personalised on-line support environment which supports
goal setting and gives access to health information (manu-
script in preparation by In-MINDD team).
In-MINDD is now testing the feasibility and accept-
ability of the LIBRA score and profile and on-line
Fig. 1 This LIBRA profile give a participant the following information. Blue segment represents their “Keep This Up” score of 67 %. The participant
is told those risk factors which they are currently managing well (in this example, cholesterol level; cognitive activity; alcohol consumption; mood;
physical activity; and smoking) or conditions which they currently do not have (heart disease; chronic kidney disease). Amber section represents
their “Room for Improvement” score of 26 %. This is made up of blood pressure; diet; and obesity. These are areas which would be targeted for
behaviour change strategies. Dark red section represents their “Remember to Manage Well” score of 7 %. This is due the participant having diabetes.
See Table 1 for a breakdown of contributing risk factors.
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pean countries: France, Ireland, the Netherlands and the
UK (namely Scotland). Primary care has been selected as
the setting as this affords an opportunity to ensure that
primary care practitioners, as well as patients, are in-
formed of the existence of the identified risk factors es-
pecially as such factors are widely prevalent in the
European population [37]. It also gives GPs an oppor-
tunity to support and motivate patients as they make,
and hopefully sustain, health-related behaviour change.
In order to do this, we are conducting a theoretically
informed feasibility randomised controlled trial and process
evaluation.
Rationale for the methodological approach
The MRC framework for complex interventions recom-
mends that before full-scale randomised controlled trials
are conducted, all stages of a trial should be fully piloted
and the feasibility of the trial approach evaluated [38, 39].
A feasibility study is designed, not to measure effective-
ness, but to assess the various components of a trial in
order to ensure that it is acceptable and feasible when
scaled up [40–42]. In particular, a feasibility trial is re-
quired when there are uncertainties about issues such as
identification of participants, recruitment and retention,
acceptability of the overall intervention or the outcome
measure on which to base a sample size calculation.
Another key consideration for optimising the learning
from a trial is having an underpinning theoretical frame-
work [24]. As described previously, the advantages oftheory in the development of a complex intervention
such as this are well reported. Theory can provide a
framework that is generalizable across settings and indi-
viduals; it provides the opportunity for the incremental
generation of knowledge and provides a framework to
guide analysis [43, 44]. It can also highlight and enhance
our understanding of the barriers to implementation and
alert us to the context into which new interventions and
services are placed [39, 45–47].
This is particularly important for a research project
such as In-MINDD, where it is crucial to understand
and evaluate issues such as participants’ understanding
of dementia prevention, the use of the on-line profiler
and support environment, as well as to test and improve
the various stages of the trial itself such as identification,
recruitment and retention of participants. In order to
fully understand the barriers and facilitators to implement-
ing and using the In-MINDD intervention in participants’
lives and in routine general practice, we need a theoretical
approach which allows us to understand the work involved
in implementing such a complex intervention. The theory
selected is Normalisation Process Theory (NPT).
NPT is a mid-range sociological theory concerned with
the work that individuals and organisations have to carry
out in order to embed and normalise new, complex ways
of working into daily routine practice [48, 49]. NPT alerts
researchers and implementers alike to the realities of im-
plementation in real time and the interactions that do, or
do not, occur between the individuals and groups charged
with that implementation [46, 50]. NPT does this by
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constructs, which are important in the implementation of
new ways of working (Table 2).
NPT will thus be used to guide the qualitative process
evaluation, when both participants and practitioners will
be interviewed about their experience and views of the
In-MINDD profiler, the LIBRA global score and profile
and the on-line support environment. These questions are
important to In-MINDD as we seek to understand how
much participants and practitioners know about the
links between modifiable risk factors and dementia risk;
whether that knowledge increases the chance of partici-
pants making and sustaining health-related behaviour
change; and whether the In-MINDD profiler and support
environment supports them in that behaviour change.
Study aims
The aim of the In-MINDD feasibility RCT is to assess
the acceptability and feasibility of giving those in mid-life,
aged between 40 and 60 years, an individualised LIBRA
brain health score and profile and access to personalised
on-line health information designed to support health-
related behaviour change. Secondly, the study aims to
understand participants’ views of dementia prevention
and explore the acceptability and integration of the
In-MINDD intervention into daily life and routine practice.
This information will be used to design and develop a defini-
tive trial. Finally, we aim to collect information on patient-
centred outcomes to determine if a change in behaviour can
be detected (i.e. proof of concept) and determine the most
appropriate main outcome measure for the main trial.
The study will thus collect a range of quantitative and
qualitative data from participants and from primary care
practitioners in four European primary care systems.
Design and methods
Study design
This is a multi-centre, primary care-based, randomised
controlled feasibility trial currently being conducted in
four European countries (France, Ireland, the Netherlands
and the UK). The trial is single-blinded. Participants, prac-
titioners and the researcher conducting the qualitativeTable 2 NPT constructs
Construct What it addresses
Coherence Can those involved in the implementation
make sense of it?
Cognitive participation Can those involved in the implementation
maintain their involvement and get others
involved and engaged?
Collective action What has to be done to make the intervention
being implemented work in routine practice?
Reflexive monitoring How can the intervention be monitored and
evaluated? Can it be re-designed?research will know the arm to which patients are allo-
cated; however, the statisticians conducting the quantita-
tive analysis will be blinded to study allocation. While it
has been powered to detect a small effect size (see below
for details) in relation to the primary outcome (i.e. reduc-
tion in overall dementia risk modification score, which will
be indicated by changes in participants’ LIBRA score be-
fore and after the trial), the principal aim is to test the
feasibility and workability of the approach in routine
primary care. This will be assessed through the use of
qualitative methods, underpinned by the theoretical ap-
proach of normalisation process theory.
The design of this protocol has followed the recom-
mendations of the SPIRIT guidelines [51, 52]. A full copy
of the SPIRIT protocol can be found in Additional file 1.
Trial registration and ethical approval
The In-MINDD RCT is registered with the ISRCTN Regis-
try: ISRCTN 98553005 (DOI: 10.1186/ISRCTN98553005).
Ethical approval has been obtained in each country in
which the RCT will be conducted, namely France, Ireland,
the Netherlands and the UK.
Recruitment
First, 6–10 general practices will be recruited in each
country; within each practice, up to 25 participants will
be recruited, giving 150 research participants per country
and a total study population of 600 patients across the
four countries. General practices will be contacted
through the existing links and networks of the in-country
research teams and selected on their interest in taking part
in the study but there will be attempts made to ensure a
spread in terms of the socioeconomic status of the prac-
tice populations.
Part of the aim of this feasibility study is to collect data
which will allow the calculation of a definitive sample size
for an effectiveness RCT. However, we did calculate that a
sample size of 600 participants will have power (0.8) to de-
tect a small effect size (of 0.187 or 0.2). This lead us to the
conclusion that 150 patients per partner country, rando-
mised into either the In-MINDD group or a control group,
will be sufficient to confidently show evidence of the effect
over the timescale of the randomised controlled trial.
Participants will be identified from practice lists by ei-
ther the research team or practice staff in Ireland, The
Netherlands and France and by a recognised proxy in
Scotland (the Scottish Primary Care Research Network).
Once eligible patients have been identified, GPs will
screen the list to ensure that only suitable participants
are approached. The researcher or practice, as appropri-
ate, will then write to eligible patients to ask if they are
interested in participating in In-MINDD. In some partici-
pating practices, the study will also be advertised to patients
through practice posters. If recruitment proves difficult
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to advertise and recruit out with general practices.
Potential participants will be sent an information pack
about In-MINDD, including participant information sheets
and an expression of interest form, which is returned to
the research team. Those who will respond will be con-
tacted by the research team and invited to meet with an
In-MINDD researcher. At that meeting, eligibility will be
confirmed and consent to participate in the study will be
obtained. We will assume a response rate of 10–20 %
(based on recent experience of recruitment for similar
studies) for our initial mailing and will repeat mailings until
our sample size has been achieved.
Inclusion and exclusion criteria
Inclusion and exclusion criteria are described in Table 3.
Baseline data collection
Baseline data will be collected from all participants
using the In-MINDD on-line profiler; clinical data will
be provided by his/her general practitioner. Data will
be collected on the following variables:Table 3 In-MINDD inclusion and exclusion criteria
Inclusion criteria
Registered with a participating practice
Age 40–60 on date of consent
Presence of any one (or more) of the following risk factors:
Depression—previous history OR active episode of minor depression
as recorded on medical record (if GP deems patient fit to participate)
Diabetes (diagnosis, e.g. on a diabetes disease register)
Hypertension (as per national guidelines)
Renal dysfunction (recorded by GP)
Obesity (BMI of 30.0 or above)
Current smoker
Raised cholesterol (as per national guidelines)
Coronary heart disease (diagnosis, e.g. on a CHD disease register)
Self-reported sedentary lifestyle
Self-reported lack of cognitive stimulation
Medically stable
Literate in language of the partner country where patient is recruited
Access to the internet in order to communicate by email and access
information online
Exclusion criteria
Active episode of major depression recorded in medical record or
assessed using a validated assessment score, e.g. Hospital Anxiety and
Depression Scale (HADS), and which GP deems makes patient too
severely ill to participate
Unable to give informed consent
Has an existing diagnosis of dementia
Other reason identified by GP, e.g. terminally ill Background information: age, sex, marital status,
employment status, education attainment, level of
occupational attainment, and living arrangements,
 General health information,
 Family medical history (i.e. existence of dementia,
cardiovascular disease and/or diabetes mellitus),
 Alcohol consumption,
 Current and past smoking habits,
 Blood pressure (obtained from general practice),
 Cholesterol level (obtained from general practice),
 Verification of diagnosis of cardiovascular disease,
renal dysfunction and diabetes (obtained from
general practice),
 General mental health and mood using the Center
for Epidemiologic Studies Depression Scale (CESD),
a short 20-item self-report scale designed to measure
symptoms associated with depression in the general
population [53],
 Physical activity using the European Prospective
Investigation into Cancer and Nutrition (EPIC)
physical activity questionnaire, which assesses
physical activity in current occupation and in leisure
and household domains in a typical week over the
past year [54],
 Cognitive activity using the Adapted Cognitive
Reserve Index questionnaire (CRIqadapted), adapted
with permission from a short instrument developed
in Italy by Nucci et al. [55] that assesses formal and
non-formal education, occupational activity and
frequency of participation in leisure time activities
over an individual’s adult life (i.e. since the age of 18),
 Diet using the Mediterranean diet adherence
screener (MEDAS), a brief dietary assessment
instrument that was developed in Spain for the
PREDIMED trial [56]. This 14-item instrument
measures adherence to a Mediterranean diet enhanced
with olive oil and nuts. Some minor adaptations have
been made to the MEDAS instruments to make it suit-
able for use in non-Mediterranean countries such as
Ireland and Scotland.
While self-reported measures can be subjected to bias
in reporting, the aim of In-MINDD is to develop a scalable
intervention which individuals can complete on-line.
Therefore, scores obtained for measures of mental health
and mood, physical activity, cognitive activity and diet, as
well as alcohol consumption and smoking will not be veri-
fied with participants’ GPs. A number of the measures,
e.g. the EPIC PAQ and Cambridge Index for physical ac-
tivity, have been shown to correlate well with self-reported
measures. In addition, with the exception of smoking and
possibly alcohol consumption, it is unlikely that GPs will
routinely collect data on the other variables of interest.
Clinical data, such as blood pressure, cholesterol, and
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and diabetes, will be checked with GPs. Where a discrep-
ancy is identified (e.g. the participants say that they do not
have CVD, but their GP says they do), both the partici-
pants and GP, with the participant encouraged to seek an
appointment with their GP to discuss this.
Once the profiler has been completed, participants will
be randomised to either the In-MINDD or control arm
of the trial (Fig. 2).
Randomisation
Participants will be randomised in equal proportions to
either (i) the In-MINDD arm or (ii) the control arm of the
trial. Randomisation will be conducted by the Robertson
Centre for Biostatistics, University of Glasgow and will beFig. 2 Flow diagram of In-MINDD RCTstratified by country and by practice. The allocation will
be derived using a computer-generated randomisation
schedule following completion of the on-line profiler. The
research team will then write to the patient to inform
them of their allocation to either the In-MINDD or con-
trol arm of the trial.
Intervention arm
Participants will receive information in form of a perso-
nalised lifestyle for brain health (LIBRA) global score and
profile based on the demographic, health behaviour and
clinical information entered into the In-MINDD profiler.
This personalised profile will highlight those areas where
they are doing well in terms of protecting their brain
health, those areas where they can make sustainable
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need to manage well (Fig. 1). Participants will have an op-
portunity, if they want, to discuss their LIBRA score,
profile and personalised plan with their GP or other
member of the general practice team, such as a practice
nurse—either face-to-face or by telephone and will also
be given access to the In-MINDD on-line support envir-
onment. This will allow them to access information on
health-related behaviours, for example advice on healthy
eating, advice on physical exercise, and links to smoking
cessation services. The In-MINDD on-line support en-
vironment also provides links to existing national web-
sites including, where possible, information on local
services. So, for example, if someone decides that they
wish to increase their physical activity, they will be
able to access information about what is available lo-
cally on relevant websites accessed through the support
environment.
Finally, the support environment incorporates goal set-
ting, again is personalised for each individual according
to their LIBRA profile. Participants will be able to set
specific goals and will be able to self-monitor progress.
They will supported by monthly email prompts regard-
ing goal setting and attainment. Goal attainment will be
assessed at the end of the 6-month trial.
At 3 months, participants will be asked to complete a
short on-line questionnaire. This will ask about the LIBRA
profile information they received, whether they have
accessed the on-line support environment, whether
they set any health behaviour change goals, and if yes,
whether they have maintained that change. They will also
be asked if they would be willing to be interviewed about
their experience so far in In-MINDD. In addition, the use
of the In-MINDD support environment will be monitored
remotely, e.g. how often they access the systems, for how
long, and what pages they visit.
After 6 months, participants will either meet with the
researcher or self-complete and update their information
on the In-MINDD system in order to generate a final
LIBRA score and profile.Control arm
Participants in the control arm will receive generic health
information material, e.g. on smoking cessation and in-
creasing physical activity. Participants in the control arm
will be asked to complete an on-line questionnaire at
3 months. They will be informed that we will contact
them towards the end of the trial period, to identify any-
one who may wish to be interviewed. At the end of the
trial period, they will either meet with the researcher or
self-complete the profiler. They will receive a copy of their
LIBRA score and profile and will be given access to the
In-MINDD on-line support environment.Process evaluation
A process evaluation will be conducted as part of the
trial, in order to understand the experience of participants
and practitioners using the In-MINDD profiler and on-
line environment. A purposive sample of participants ap-
proaching the end of the trial period will be asked if they
are willing to participate in a face-to-face interview. At the
end of the trial, a sample of participants will be selected
from those agreeing to be approached for interview or
focus group. A minimum of five patients will be inter-
viewed in each country (more in Ireland and Scotland,
where interviews can be conducted in English and not
need to be translated for analysis); interviewees will be
selected on the basis of LIBRA score (high and low),
gender (male and female). Interviews will be conducted
at a time and place convenient to the interviewee and
will last approximately 1 h. Interviews will explore their
views of the information they received from the profiler,
their use of the on-line support environment, how they
did/did not incorporate recommendations into their
daily life, and their perception of the overall impact of
the In-MINDD experience. A smaller group of participants
in the control group (n = 10) will also be interviewed in
order to ascertain whether the information they received
increased their understanding of the modifiable risk factors
for dementia and whether they made any lifestyle changes.
Efforts will also be made to obtain an understanding of
why participants did not complete the trial by including a
sample of those who dropped out.
We will also interview a sample of health professionals
from participating practices to understand their expecta-
tions and opinion about reducing dementia risk and the
In-MINDD system. We will recruit GPs, practice nurses
and other appropriate staff members from participating
practices in Ireland and Scotland. Staff will be interviewed
about their views of dementia, the use of risk scores and
how such information is shared with patients, preventive
strategies for dementia, and the In-MINDD profiler.
Data analysis will use recognised methods of qualita-
tive analysis [57], underpinned by Normalisation Process
Theory [46, 49, 50]. Analyses will be conducted both
within country and by sharing anonymised transcripts
between countries via video-conferenced data coding
clinics.Improving adherence
We will monitor the use of the In-MINDD on-line support
environment remotely, e.g. how often they access the sys-
tems, for how long and what pages they visit. Questionnaires
at 3 and 6 months will assess what areas of lifestyle behav-
ioural change participants targeted, e.g. smoking cessation,
taking up a new hobby such as learning a language, and to
what extent they have maintained that activity. Participants
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at either 3 or 6 months, we will be able to contact the
practice to ascertain if the patient is still registered with
the practice or if they have left. This will be documented
by the local country team. We will not, however, remove
patients from the trial if they do not use the In-MINDD
on-line environment, as sustainability of use is a key re-
search questions.
Discontinuing or modifying the intervention
Participants will be able to leave the trial, if they wish to,
at any time and for any reason. An end of trial form will
be completed for all trial members, detailing the reason
for leaving the trial, e.g. choosing to leave, illness, death,
and loss to follow-up.
As this is a feasibility trial, we are particularly interested
in monitoring the sustainability of use of the In-MINDD
intervention. This is not a medical or pharmaceutical
intervention, so we will not modify the delivery of the
intervention but, instead, monitor how participants use
and adapt the system to suit their own needs. In particular,
we are interested to explore if giving participants informa-
tion about modifiable risks for dementia prompts them to
modify their daily activities.
While we do not plan to alter the In-MINDD interven-
tion within this feasibility study, the data generated from
the process evaluation will be used to develop and modify
the in-line profiler and support environment for future
use.
We have not planned to provide GPs with training into
the area of dementia prevention, instead relying on their
current knowledge of risk factors associated with the later
development of dementia and, in particular, their know-
ledge on advising patients on strategies to initiate and
support health-relate behaviour change, such as smoking
cessation or exercise uptake. This approach was supported
by those GPs who were consulted during earlier co-design
of the on-line profiler. Participating GPs did, however,
have access to the In-MINDD materials made available
to the participants, and they had the opportunity to ask
questions of the research team if required. The process
evaluation will, however, explore their views of this and
should provide valuable information to promote the de-
sign and delivery of future training.
Outcomes
Primary outcome measure is change in dementia risk modi-
fication (LIBRA) score over the 6 months of the trial,
calculated on the basis of a basket of individual risk fac-
tors identified by earlier work in In-MINDD [12]. These
will include physical and cognitive activity, mood, presence
or absence of diabetes, chronic kidney disease and/or
cardiovascular disease, high cholesterol, adherence to a
Mediterranean diet, smoking status, alcohol consumption,hypertension, and obesity. Secondary outcomes will be
changes in individual risk factors.
Analyses plan
Analyses will be conducted by the Robertson Centre
for Biostatistics, University of Glasgow. The primary
outcome—the dementia risk modification score—will
be analysed using a linear regression model, with a
binary term for intervention group, and adjusting for
the baseline risk score and country. This model will be
extended to investigate baseline predictors of outcome,
with interaction terms added to assess subgroup differ-
ences (e.g. age) in any intervention effect. Similar methods
will be applied to individual risk factors. Modelling as-
sumptions will be assessed through examination of residual
distributions, and data transformations or generalised lin-
ear models will be used where appropriate. All analyses will
be by intention to treat, i.e. in relation to randomised allo-
cation, regardless of adherence to or uptake of the inter-
vention. Multiple imputations will be used for any missing
baseline information. Missing outcome data will not be im-
puted in the first instance, but the sensitivity of results to
alternative assumptions will be assessed. Where appropri-
ate, data will be presented with 95 % confidence intervals.
Feasibility outcomes
A key part of this RCT will be to determine a set of
feasibility outcomes to inform the development of a full-
scale effectiveness trial. Feasibility outcomes are those
outcomes which relate to the successful implementation
and completion of the trial, including the route and ease
of recruitment, ability of participants to enter and remain
in the trial, and the ability of participants to complete the
profiler.
Parameters on which feasibility will be judged
Our principle parameters to determine the success of
our feasibility study are:
1. Ease of recruitment—can we identify and recruit
eligible patients in primary care, through general
practices.
2. Successful completion of the profiler, with a loss to
follow-up of no more than 20 % (i.e. completion rate
of 80 % or more).
3. Evidence that the profiler is not harmful to patients,
i.e. that there is no systematic worsening of LIBRA
score in the intervention group compared to controls
over the time period.
Monitoring and patient safety
Monitoring of trial recruitment will be conducted by each
partner country, using a trial timetable template. Trial
coordinators in each country will communicate their
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in the University of Glasgow. Monitoring of the overall
trial will be the responsibility of the trial monitoring com-
mittee. Serious adverse events (SAEs) are not anticipated
during this trial, but unanticipated adverse events are al-
ways possible. Attempts will be made to monitor patients
who are lost to follow-up or who drop out; practices will
be asked about such patients in order to identify if the
patient has experienced a harmful event (e.g. hospital
admission, death) which could be attributed to In-MINDD.
This will be recorded and sent to the trial monitoring
committee.
Discussion
Dementia is a growing challenge for health systems in the
twenty-first century. There is, however, growing evidence
that there are modifiable risk factors which can contribute
to an individual’s risk of developing dementia in later life.
In-MINDD has a key role to play both in raising awareness
of this amongst the public and primary care practitioners
and, through utilising the potential benefits of internet-
based, personalised health prevention strategies and to
alleviate the problem. Testing the intervention in a robust
and theoretically informed manner will pave the way for a
future, full-scale RCT.
Trial status
Practice recruitment was initiated in June 2014. Patient
recruitment began in October 2014 and is ongoing until
June 2015. The trial will conclude in early 2016.
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